Fibroblast Growth Factor 23 and Adverse Clinical Outcomes in Type 2 Diabetes: a Bitter-Sweet Symphony

PURPOSE OF REVIEW: Fibroblast growth factor 23 (FGF23) is a key phosphate-regulating hormone that has been associated with adverse outcomes in patients with chronic kidney disease (CKD). Emerging data suggest that FGF23 plays a specific role in type 2 diabetes, partly independent of kidney function....

Descripción completa

Detalles Bibliográficos
Autores principales: Yeung, Stanley M. H., Bakker, Stephan J. L., Laverman, Gozewijn D., De Borst, Martin H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2020
Materias:
Microvascular Complications—Nephropathy (B Roshanravan, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455586/
https://www.ncbi.nlm.nih.gov/pubmed/32857288
http://dx.doi.org/10.1007/s11892-020-01335-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7455586/
https://www.ncbi.nlm.nih.gov/pubmed/32857288
http://dx.doi.org/10.1007/s11892-020-01335-7

Ejemplares similares